Regulation of NADH: ubiquinone oxidoreductase (complex *
Project Number5R03TW006041-02
Contact PI/Project LeaderCECCHINI, GARY
Awardee OrganizationNORTHERN CALIFORNIA INSTITUTE/RES/EDU
Description
Abstract Text
DESCRIPTION (provided by applicant) NADH:ubiquinone oxidoreductase (complex I) is an energy-transducing membrane-bound protein complex that serves as a major entry point for electrons to the mitochondrial respiratory chain. The multisubunit enzyme complex is encoded by 43 separate genes in mammals. The mammalian enzyme shows extremely complex kinetic behavior, in all forms that retain natural electron transfer pathways. The complex kinetic behavior suggests that two distinct slowly equilibrating forms of the enzyme exist. The active (A) form is catalytically capable to reduce ubiquinone, whereas, the de-active (D) form is not able to transfer electrons to ubiquinone in the membrane. The equilibrium between these two forms is under a refined control by a number of regulatory factors (i.e., pH, divalent cations, temperature, the ubiquinone/ubisemiquinone/ubiquinol ratio). This research will primarily be done in Russia as an extension of NIH grant R01 GM61606. The proposed collaborative work is to extend studies of the regulatory characteristics of the enzyme at the molecular mechanistic level by using a combination of biochemical and molecular approaches. The studies will be done in physiologically relevant systems such as intact hearts and mitochondria, as well as, the kinetic and biochemical approaches in the foreign Co-P.l.'s laboratory. Two major aspects of the ND transition are to be investigated. One is to elucidate the molecular mechanisms of the slow interconversion between the A and D forms involved in the red/ox-dependent D to A transition; and the extremely temperature-dependent A to D transition. Natural ligands and modifiers which affect the rate and equilibrium of the ND transition in vitro will be identified. The second aim focusses on the complex I A/D transition in intact mitochondria in relation to the experimental model of ischemia/reperfusion in Langendorff-pertused rat hearts. The focus of these studies is to determine the possible physiological importance of the A/D transition of complex I as it responds to alterations in cellular metabolism. The catalytic activity of complex I is important for cellular physiology and a number of diseases (diabetes, cardiomyopathy) have been associated with defects in complex I. The research to be undertaken will shed light on the modulation of enzyme activity of this important respiratory complex.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Commonwealth of Independent StatesNAD(P)H oxidoreductaseSDS polyacrylamide gel electrophoresisactive sitesbinding sitescomplementary DNAcooperative studyenzyme structureenzyme substratelaboratory ratligandsmitochondriamutantmyocardial ischemia /hypoxianucleic acid sequenceprotein purificationreperfusionubiquinone
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
989
DUNS Number
613338789
UEI
NJZEFMRACCH9
Project Start Date
15-August-2002
Project End Date
30-June-2005
Budget Start Date
01-July-2003
Budget End Date
30-June-2004
Project Funding Information for 2003
Total Funding
$42,815
Direct Costs
$32,000
Indirect Costs
$10,815
Year
Funding IC
FY Total Cost by IC
2003
John E. Fogarty International Center for Advanced Study in the Health Sciences
$42,815
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03TW006041-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03TW006041-02
Patents
No Patents information available for 5R03TW006041-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03TW006041-02
Clinical Studies
No Clinical Studies information available for 5R03TW006041-02
News and More
Related News Releases
No news release information available for 5R03TW006041-02
History
No Historical information available for 5R03TW006041-02
Similar Projects
No Similar Projects information available for 5R03TW006041-02